AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
Log in

TSE:CXRConcordia International Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume73,500 shs
Average Volume4,054 shs
Market CapitalizationC$1.22 billion
P/E Ratio0.07
Dividend YieldN/A
BetaN/A
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Read More
Concordia International logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-8425150

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$569.62 million
Book ValueC$6.08 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$1.22 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive CXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CXR and its competitors with MarketBeat's FREE daily newsletter.

Concordia International (TSE:CXR) Frequently Asked Questions

Has Concordia International been receiving favorable news coverage?

News stories about CXR stock have trended negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concordia International earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutConcordia International.

Who are some of Concordia International's key competitors?

What other stocks do shareholders of Concordia International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concordia International investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET), Concordia International (CXRX), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

Who are Concordia International's key executives?

Concordia International's management team includes the following people:
  • Mr. Graeme Neville Duncan, CEO & Director (Age 44)
  • Mr. Karl Ian Belk, Chief Operations Officer
  • Mr. Adeel Ahmad, Chief Financial Officer (Age 44)
  • Mr. Adam Peeler, VP of Investor Relations & Communications
  • Mr. Robert Sully, Gen. Counsel

What is Concordia International's stock symbol?

Concordia International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."

How do I buy shares of Concordia International?

Shares of CXR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is Concordia International?

Concordia International has a market capitalization of C$0.00 and generates C$569.62 million in revenue each year.

What is Concordia International's official website?

The official website for Concordia International is concordiarx.com.

How can I contact Concordia International?

Concordia International's mailing address is 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada. The company can be reached via phone at +1-905-8425150.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.